Sign In
Buy DNA
$7.89
-0.110 (-1.38%)
At Close: Jun 12, 2026
ProteoNic licenses its 2G UNic technology to Ginkgo Bioworks for a BARDA-backed consortium to boost fast, cost‑effective mAb production against filoviruses
Ginkgo Bioworks partners on Deep Origin-led team to develop new tools for predicting drug safety
08:00am, Tuesday, 09'th Dec 2025
BOSTON , Dec. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with Deep Origin on a 4.5-year project funded by the Advanced Research Projects Agency for Health (AR
This strengthens NeuralCloud's expansion into the global wellness and B2B health practitioner delivery model with high-fidelity cardiac signal processing and digital health integration. Partnership po
Ginkgo Bioworks Selected by PNNL to Deliver a Modular, High‑Throughput Phenotyping Platform for DOE's M2PC
08:33am, Friday, 05'th Dec 2025
BOSTON , Dec. 5, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced it has been awarded by the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laborator
STRM.BIO Awarded ARPA-H Contract to Advance Megakaryocyte-Derived Vesicle Platform for In Vivo Cell Engineering and Gene Therapy
08:00am, Wednesday, 03'rd Dec 2025
CAMBRIDGE, Mass. , Dec. 3, 2025 /PRNewswire/ -- STRM.BIO, a start-up biotechnology company pioneering non-viral delivery technologies for in vivo cell and gene therapy, today announced that it has bee
Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health
08:00am, Tuesday, 18'th Nov 2025
BOSTON , Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year
Ginkgo Bioworks: Not There Yet
02:15am, Tuesday, 11'th Nov 2025
Ginkgo Bioworks shares dropped on Friday as revenue growth continues to disappoint and cash burn persists despite improvements. Q3 results missed expectations, with adjusted revenues tumbling and oper
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
08:26pm, Thursday, 06'th Nov 2025
Ginkgo Bioworks Holdings, Inc. ( DNA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Daniel Waid Marshall Jason Kelly - Founder, CEO & Director Steven Coen - Chief Accounting
Ginkgo Bioworks Reports Third Quarter 2025 Financial Results
04:05pm, Thursday, 06'th Nov 2025
Ginkgo provides an update on its third quarter financial results BOSTON , Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the third qu
New environmental DNA test could help rare hammerhead sharks fight extinction
12:03pm, Wednesday, 05'th Nov 2025
/PRNewswire/ -- A groundbreaking test developed by an FIU scientist can detect small, elusive hammerheads without ever setting eyes on them — a critical new
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules
09:00am, Monday, 03'rd Nov 2025
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technology DNA delivery technology to be offered as GenePhore™ to biotech / pharma companies Addressing large
Ginkgo Bioworks Awarded Project Agreement through BARDA's BioMaP-Consortium
08:00am, Monday, 03'rd Nov 2025
Ginkgo and Partners to Develop Monoclonal Antibody Biomanufacturing Innovations and to Produce an Anti-Filovirus Medical Countermeasure BOSTON , Nov. 3, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA
DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars
12:01pm, Friday, 31'st Oct 2025
Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.
BOSTON , Oct. 31, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that the company has extended its multi-year strategic partnership with Bayer to advance research and development of
Ginkgo Bioworks Announces Date of Third Quarter 2025 Results Presentation
04:05pm, Thursday, 30'th Oct 2025
Presentation and Q&A session scheduled for post-market on Thursday, November 6, 2025 BOSTON , Oct. 30, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it
